ArticleBMJ open2020

Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.

Nitichen Kittiratchakool et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.